Most clinical experience involves short-term therapies, typically for less than a year
Most women begin with one or two targeted peptides, monitor their response over a cycle of roughly six to twelve weeks, and expand only if it makes sense
By combining complementary peptides, we can create a multi-pronged approach to wellness that a single peptide cant achieve alone
From the second use onward, every actuation introduces unprotected microbial risk
Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3
In contrast, injections deliver the peptide directly into the bloodstream or localized injury site, allowing for faster action and more targeted healing